Schizophrenia drug claims questioned

Key points
- Scientists have raised concerns that claims about the benefits of a new generation of drugs for conditions such as schizophrenia may have been exaggerated.
- Marjorie Wallace, chief executive of mental health charity SANE, expressed concern that the benefits of the newer drugs was being questioned.
- Not only are the new antipsychotic drugs - known as atypicals - thought to be more effective, they have also been associated with fewer side effects.
- However, a new study has questioned whether they are actually as relatively side effect free as was thought.
Scientists have raised concerns that claims about the benefits of a new generation of drugs for conditions such as schizophrenia may have been exaggerated.
Not only are the new antipsychotic drugs - known as atypicals - thought to be more effective, they have also been associated with fewer side effects.
However, a new study has questioned whether they are actually as relatively side effect free as was thought.
The drugs, which include risperidone, quetiapine, clozapine and olanzapine, have been approved for use by the NHS by the National Institute for Clinical Excellence (NICE).
However, they are very expensive, and campaigners are concerned that they have only been made available to a small minority of patients who would benefit.
The latest study has examined concerns that the drugs' reputation for being side effect free is unjustified - largely because initial trials compared them with a particularly potent older generation drug called haloperidol.
A team from Zucker Hillside Hospital in New York lead by Dr Stefan Leucht carried out a comprehensive review of data from 31 studies which involved 2,320 patients.
Of the new generation drugs, only clozapine was associated with fewer neurological side-effects and higher efficacy than low-potency conventional drugs.
"In a significant number of cases (by no means everyone) atypical drugs can transform lives in a way in which the older drugs have failed "
Marjorie Wallace
And as a group, new-generation drugs were only moderately more efficacious than low-potency conventional antipsychotics.
Dr Leucht said: "If these findings are confirmed by future studies, there would be a good argument for the use of appropriately dosed conventional drugs - such as chlorpromazine - for patients with schizophrenia in settings where new-generation drugs are not generally affordable."
Concern
Marjorie Wallace, chief executive of mental health charity SANE, expressed concern that the benefits of the newer drugs was being questioned.
She said: "All drugs, if they are to be effective, will have side effects, but our experience is that for the majority the side effects of the newer drugs are more tolerable, people are more willing to take them and they are therefore more effective.
"In a significant number of cases (by no means everyone) atypical drugs can transform lives in a way in which the older drugs have failed."
Paul Corry, of the charity Rethink, said much more research was needed before a switch away from the newer drugs could be seriously considered.
"People generally prefer the new atypical antipsychotics because they are associated with fewer and less severe side effects.
Written and revised by
Gerald Hurowitz, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Mental Health →
NewsNew Clues to Schizophrenia Pathogenesis
The composition of the oropharyngeal virome in patients with schizophrenia differs from that of healthy persons, and understanding the pathologic consequences of these differences may open up new avenues for therapeutic…
13 July 2015
NewsStudy identifies brain abnormalities in people with schizophrenia
Structural brain abnormalities in patients with schizophrenia, providing insight into how the condition may develop and respond to treatment, have been identified in an internationally collaborative study led by a…
8 July 2015
NewsLong-acting antipsychotic medication may improve treatment for schizophrenia
Schizophrenia, which affects 2 million to 3 million people in the U.S., causes hallucinations, delusions and disorganization. Left untreated, the disease can cause a significant loss in quality of life, including…




